Research Topics
| Arnold R GammaitoniSummaryAffiliation: Endo Pharmaceuticals Country: USA Publications
| Collaborators
|
Detail Information
Publications
Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back painBradley S Galer
Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
Curr Med Res Opin 20:S5-12. 2004..To determine the impact of the lidocaine patch 5% on pain qualities associated with low-back pain (LBP) through use of the Neuropathic Pain Scale (NPS)...- Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain ScaleArnold R Gammaitoni
Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
Curr Med Res Opin 20:S13-9. 2004..e.sharp, dull)... - Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosingArnold R Gammaitoni
Endo Pharmaceuticals, 100 Painters Dr, Chadds Ford, PA 19317 9007, USA
Ann Pharmacother 36:236-40. 2002..To assess the pharmacokinetics, safety, and tolerability of lidocaine delivered via 4 lidocaine 5% patches applied for 18 h/d for 3 consecutive days in healthy volunteers... - Pharmacokinetics and safety of continuously applied lidocaine patches 5%Arnold R Gammaitoni
Endo Pharmaceuticals Inc, 100 Painters Drive, Chadds Ford, PA 19317, USA
Am J Health Syst Pharm 59:2215-20. 2002..Mild application-site erythema occurred in most patients, but no systemic adverse reactions were judged to be related to the patches. No loss in sensation at the application site was reported... - Clinical application of opioid equianalgesic dataArnold R Gammaitoni
Endo Pharmaceuticals, Inc, Chadds Ford, Pennsylvania 19317, USA
Clin J Pain 19:286-97. 2003..This approach may help to build a comfort level when dealing with the clinical challenges of converting from one opioid to another... - Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back painArnold R Gammaitoni
Endo Pharmaceuticals Inc, Chadds Ford, Pennsylvania 19317, USA
Pain Med 4:21-30. 2003..5- and 10-mg/acetaminophen 325-mg (Percocet) formulations in patients with low back pain (LBP) suboptimally responsive to nonsteroidal anti-inflammatory drugs, muscle relaxants, tramadol, cyclo-oxygenase-2 inhibitors, and/or prn opioids... 
The pain quality response profile of oxymorphone extended release in the treatment of low back painErrol M Gould
Endo Pharmaceuticals Inc, Chadds Ford, PA 19317, USA
Clin J Pain 25:116-22. 2009..This study sought to evaluate the utility of assessing the multiple components of non-neuropathic pain in an analgesic clinical trial...- Randomized, double-blind, placebo-controlled comparison of the analgesic efficacy of oxycodone 10 mg/acetaminophen 325 mg versus controlled-release oxycodone 20 mg in postsurgical painArnold R Gammaitoni
Endo Pharmaceuticals, Inc, 100 Painters Drive, Chadds Ford, PA 19317, USA
J Clin Pharmacol 43:296-304. 2003..This new formulation offers the combination of two analgesic drugs with complementary mechanisms of action, which results in enhanced analgesia, an "opioid-sparing" effect, and an improved side effect and safety profile... - Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritisBradley S Galer
Endo Pharmaceuticals, Inc, Chadds Ford, PA 19317, USA
Curr Med Res Opin 20:1455-8. 2004..Topical lidocaine patch 5% may provide clinicians with a novel, non-systemic therapy for OA pain with a unique mechanism of action... - Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literatureArnold R Gammaitoni
Endo Pharmaceuticals, 100 Painters Drive, Chadds Ford, PA 19317, USA
J Clin Pharmacol 43:111-7. 2003..The lidocaine patch provides a treatment option that carries a relatively low systemic adverse event and drug-drug interaction risk burden, even with continuous application of up to four patches per day... - Comparison of the pharmacokinetics of oxycodone administered in three Percocet formulationsArnold R Gammaitoni
Endo Pharmaceuticals, Inc, Chadds Ford, Pennsylvania 19317, USA
J Clin Pharmacol 42:192-7. 2002..Increasing dose levels of oxycodone/acetaminophen provides proportional increases in oxycodone Cmax and AUC. Adverse events were predictable based on the opioid pharmacologic actions of this agent... - The dimensions of pain quality: factor analysis of the Pain Quality Assessment ScaleTimothy W Victor
Endo Pharmaceuticals Inc, Chadds Ford, PA 19317, USA
Clin J Pain 24:550-5. 2008..To provide a better empirical understanding of the dimensionality of neuropathic and non-neuropathic pain quality... - Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain ScaleCharles E Argoff
Cohn Pain Management Center, North Shore University Hospital NYU School of Medicine, Bethpage, NY 11714, USA
Curr Med Res Opin 20:S21-8. 2004..To determine the impact of the lidocaine patch 5% on pain qualities associated with chronic pain from postherpetic neuralgia (PHN), painful diabetic neuropathy (DN), and low-back pain (LBP), using the Neuropathic Pain Scale (NPS)... 
A comparison of the lidocaine patch 5% vs naproxen 500 mg twice daily for the relief of pain associated with carpal tunnel syndrome: a 6-week, randomized, parallel-group studySrinivas Nalamachu
Kansas City University of Medicine and Biosciences, Kansas City, Missouri, USA
MedGenMed 8:33. 2006..This pilot clinical trial was designed to compare the safety and effectiveness of the lidocaine patch 5% to that of naproxen 500 mg twice daily for the treatment of neuropathic pain associated with CTS...- Effectiveness of lidocaine patch 5% in patients with or without allodyniaArnold R Gammaitoni
CNS Spectr 11:906. 2006 - The pain quality assessment scale: assessment of pain quality in carpal tunnel syndromeMark P Jensen
Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, Washington, USA
J Pain 7:823-32. 2006..Measures such as the PQAS can potentially be used to help clinicians target analgesics more efficiently... - Symptom profiles differ in patients with neuropathic versus non-neuropathic painRobert H Dworkin
Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
J Pain 8:118-26. 2007.... - Do pain qualities and spatial characteristics make independent contributions to interference with physical and emotional functioning?Mark P Jensen
Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, 98195 6490, USA
J Pain 7:644-53. 2006..These findings suggest that measures of these specific pain domains could play an important role in understanding the impact of pain on patient functioning... - Assessment of pain quality in chronic neuropathic and nociceptive pain clinical trials with the Neuropathic Pain ScaleMark P Jensen
Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
J Pain 6:98-106. 2005..This research might be used to help clinicians target analgesics to match the specific qualities associated with a patient's pain and to better understand the mechanisms of analgesic effects in drug development programs... - More than 7 years of consistent neuropathic pain relief in geriatric patientsBradley S Galer
Arch Intern Med 163:628. 2003 - Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathwaysMichael Adams
SFBC-New Drug Services Inc, Kennett Square, Pennsylvania, USA
J Clin Pharmacol 45:337-45. 2005..Oxymorphone ER exhibits a minimal potential for causing metabolic drug-drug interactions mediated by CYP2C9 or CYP3A4...